Histogen, Inc.
(NASDAQ : CNAT)

( )
CNAT PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 1.11%62.180.0%$1999.69m
REGNRegeneron Pharmaceuticals, Inc. -2.18%599.472.5%$1212.04m
GILDGilead Sciences, Inc. -3.43%75.161.0%$972.03m
NVAXNovavax, Inc. 14.73%52.82102.0%$711.68m
AMGNAmgen, Inc. -1.22%226.911.3%$619.06m
VRTXVertex Pharmaceuticals, Inc. -0.46%286.641.9%$592.02m
BIIBBiogen, Inc. -1.84%301.451.6%$385.60m
ILMNIllumina, Inc. 0.65%365.413.5%$384.25m
SRNESorrento Therapeutics, Inc. -0.99%5.001.8%$320.03m
ALXNAlexion Pharmaceuticals, Inc. -0.82%118.922.0%$296.17m
SGENSeattle Genetics, Inc. 1.15%159.026.1%$258.80m
AAgilent Technologies, Inc. 2.01%89.911.6%$212.68m
BMRNBioMarin Pharmaceutical, Inc. 0.79%107.394.3%$185.56m
MGNXMacroGenics, Inc. 9.67%21.106.2%$174.18m
INCYIncyte Corp. -0.16%101.752.5%$166.58m

Company Profile

Conatus Pharmaceuticals, Inc. is a biotechnology company that focuses on the development and commercialization of novel medicines to treat chronic diseases. The firm engages in developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease and is designed to reduce the activities of human caspases. It also develops CTS-2090, an orally active selective caspase inhibitor, for diseases involving inflammasome pathways. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, and Steven J. Mento on July 13, 2005 and is headquartered in San Diego, CA.